Renoprotective effects of dulaglutide in patients with T2DM and CKD

Renoprotective effects of dulaglutide in patients with T2DM and CKDRenoprotective effects of dulaglutide in patients with T2DM and CKD, Published online: 31 August 2018; doi:10.1038/s41581-018-0055-xThe AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Source Type: research